Veradigm | MDRX - Sales Revenues


Veradigm reported $142.52M in Sales Revenues for its fiscal quarter ending in December of 2022.





Sales Change Date
Alcidion AUD 25.47M 2.32M Dec/2025
Ambu A/S DKK 1.57B 10M Mar/2026
Amplifon EUR 606M 26.1M Jun/2026
Cardinal Health USD 63.7B 2.8B Jun/2026
Centene USD 53.58B 3.64B Jun/2026
Charles River Laboratories USD 1000M 4.2M Jun/2026
Cigna USD 71.7B 3.18B Jun/2026
Coloplast 7.04B 83M Dec/2025
Convatec Group USD 1.26B 80M Dec/2025
CVS Health USD 106.1B 5.7B Jun/2026
Diasorin EUR 315M 22.49M Jun/2026
Elevance Health USD 49.8B 300M Jun/2026
General Electric Aerospace USD 12.63B 1.03B Jun/2026
Gulf Medical Proj AED 194.39M 19.38M Mar/2026
Humana USD 40.89B 1.24B Jun/2026
IQVIA Holdings USD 4.37B 220M Jun/2026
Laboratory Of America USD 3.73B 190M Jun/2026
Maximus USD 1.28B 30M Jun/2026
McKesson USD 105.38B 13.08B Jun/2026
Med Life RON 853M 65.04M Mar/2026
Molina Healthcare USD 10.87B 70M Jun/2026
Omnicell USD 312.21M 2.33M Jun/2026
Oriola-kd EUR 49.8M 452.2M Mar/2026
Owens Minor USD 708.97M 11.71M Dec/2025
Quest Diagnostics USD 3.04B 140M Jun/2026
Rede D'or Sao Luiz BRL 14.91B 350M Jun/2026
Siemens Healthineers EUR 5.76B 80M Jun/2026
Sonova Holding CHF 1.82B 216.8M Dec/2025
Supermax Corporation Bhd MYR 126.8M 60.64M Mar/2026
UnitedHealth USD 112B 300M Jun/2026
Veeva Systems USD 882.95M 47M Mar/2026
Veradigm USD 142.52M 9.38M Dec/2022
Xerox USD 2.03B 70M Dec/2025